Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Oragenics, Inc.

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics, Inc. Files 10K and Provides Company Update
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics Announces Closing of Public Offering
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics Announces Pricing of Public Offering
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics Announces Proposed Public Offering
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics, Inc. Announces Leadership Transition
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics Announces Termination of At-The-Market Offering Program
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
From Oragenics, Inc.
Via Business Wire
Tickers ODYY OGEN
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics, Inc. Announces Private Placement
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics to Participate in the World Vaccine Congress Washington
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics, Inc. Regains Compliance with NYSE American
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics, Inc. Receives NYSE American Notice
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics, Inc. Announces New Chair
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics to Participate in the 2022 BioFlorida Annual Conference
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics Issues Letter to Shareholders
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
From Oragenics, Inc.
Via Business Wire
Tickers OGEN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.